Rising risk: Maximizing the odds for care management

Similar documents
Risk adjustment and the power of four

Strategies for Assessing Health Plan Performance on Chronic Diseases: Selecting Performance Indicators and Applying Health-Based Risk Adjustment

Milliman RBRVS for Hospitals

PART 2: ACTUARIAL ISSUES IN CARE MANAGEMENT INTERVENTIONS. Paper 4: Understanding the Economics of Disease Management Programs

Milliman RBRVS for Hospitals

Predictive Analytics and Technology Session

Using Analytics To Transform Your ACO

Session 77PD, Risk Adjustment and the Impact on Value-Based Payments. Presenters: David Dobberfuhl, FSA, MAAA Johann K.

Data Analytics Solutions

Article from. Predictive Analytics and Futurism. June 2017 Issue 15

Risk Adjusted Episodes as Benchmarks for ACOs: A Society of Actuaries Sponsored Study

High Cost Claim Prediction for Actuarial Applications

Article from: Health Section News. August 2003 Issue No. 46

2.05 Predictive Modeling P4P and Physician Engagement. Pay for Performance Summit February 7, 2006

Building Actuarial Cost Models from Health Care Claims Data for Strategic Decision-Making. Introduction. William Bednar, FSA, FCA, MAAA

Consumer Directed Health Care: A Look at Current Experience

Factors Affecting Individual Premium Rates in 2014 for California

Texas Medicaid Managed Care Cost Impact Study

Re: Comments on proposed rule for the Medicare Shared Savings Program: Accountable Care Organizations

Accolade: The Effect of Personalized Advocacy on Claims Cost

Innovation with proven results: Enhanced Personal Health Care

Savings Impact of Community Care of North Carolina: A Review of the Evidence

Understanding the 2020 Medicare Advantage Advance Notice Part I

Predicting, and preventing costblooms. Nigam Shah, MBBS, PhD

We are experiencing the most rapid evolution our industry

Determining discounts

Developing an All-Patient Risk Model in a Unified Analytics Environment

Presented by: Steven Flores. Prepared for: The Predictive Modeling Summit

Health Plans Dashboard

Using Predictive Analytics to Better Understand Morbidity

Value-Based Payment Reform Academy: What to Consider when Designing a Risk Adjustment Strategy for Value-based APMs for FQHCs

Session 66 L, Value Based Approach for the Medicare Advantage Market. Presenters: Julia Friedman, FSA, MAAA Matthew Kranovich, FSA, MAAA

Traditional Approach with a New Twist. Medical IBNR; Introduction. Joshua W. Axene, ASA, FCA, MAAA

Independent Evaluation of Trend Development Methodology

Calculating Accurate Metrics for the Actuarial Cost Model. Introduction. William Bednar, FSA, FCA, MAAA

Integrating Population Health Analytics and the EHR Environment Session 87, March 6, 2018

Controlling Healthcare Costs through Innovative Methods - Analytics

Restructuring the Medicare Part D Benefit with Capped Beneficiary Spending

Milliman Risk Score 2.0 stratifying mortality risk using prescription drug information

IMPACT OF TELADOC USE ON AVERAGE PER BENEFICIARY PER MONTH RESOURCE UTILIZATION AND HEALTH SPENDING

Sent via electronic transmission to:

Session 22 IF, ACA Transitional Solvency Risks. Moderator/Presenter: Samuel C. Vorderstrasse, FSA, MAAA

Estimating measurement error when annualizing health care costs

Successful disease management

Neutrality risk management in ICD-10 remediation

The Health Insurance Market in Virginia. Maureen Dempsey, MD, MSc, ACC, FAAP Anthem Blue Cross and Blue Shield June 8, 2017

ACO Benchmarks and Financial Success SOA Sponsored Research

Disease Management Initiative. Legislative Authorization. Program Objectives

Self-funding can give employers more control over every aspect of their medical insurance programs

Technical Appendix. This appendix provides more details about patient identification, consent, randomization,

Committee on Ways and Means U.S. House of Representatives. Hearing on Expanding Coverage of Prescription Drugs in Medicare.

Workplace Products SEAC Fall Meeting Atlanta, Georgia November 21, Disclaimer

Lehigh Valley Health Network

MAHP: Who We Are. The Michigan Association of Health Plans is a nonprofit corporation established to promote the interests of member health plans.

For the RRU Index Ratio, an EXC is displayed if the denominator is <200 for the condition or if the calculated indexed ratio is <0.33 or >3.00.

Producing actionable insights from predictive models built upon condensed electronic medical records.

2013 Milliman Medical Index

Medicare at 50. R. B. Drennan, PhD Associate Professor Fox School of Business Temple University 28 January 2016

Post-Acute and Long-Term Care Reform / Estimating the Federal Budgetary Effects of the AHCA/NCAL/Alliance Proposal

MEASURING THE IMPACT OF POINT OF SALE REBATES IN COLORADO S COMMERCIAL MARKET

Temple University Health System Q2 FY Investors Update Conference Call. March 19, 2019

Consumer-Driven Health Plans: A Cost and Utilization Analysis

The Shocking Truth Behind ACA Premium Changes: It s Complicated

MANAGERIAL. APrediction Model for Targeting Low-Cost, High-Risk Members of Managed Care Organizations

Merit-Based Incentive Payment System (MIPS): ST-Elevation Myocardial Infarction (STEMI) with Percutaneous Coronary Intervention (PCI) Measure

S E C T I O N. National health care and Medicare spending

P r e p a r i n g f o r G l o b a l P a y m e n t : W h a t Yo u S h o u l d B e D o i n g N o w

Medicare Advantage star ratings: Expectations for new organizations

The Impact of Program Changes on Health Care for the OHP Standard Population: Early Results from a Prospective Cohort Study

Health Information Technology and Management

2009 Milliman Medical Index

IFRS17 Implementation A new reporting framework comes with significant challenges

Reinsurance Section News

INFORMATION ABOUT YOUR OXFORD COVERAGE

2016 ICCMHC CONFERENCE

The Potential for Predictive Analytics in a Pediatric Care Setting A Case Study

MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR ASCENSION

Medical Underwriting: Approaches and Regulatory Restrictions

A CONSUMER S GUIDE TO CANCER INSURANCE

Alaska Comprehensive Chronic & Acute Medical Cost Reduction and Containment Program. Presentations By: David Morgan and Ross Bieling

RRU Frequently Asked Questions

Session 38PD, Use of Big Data to Optimize Plan Design. Moderator/Presenter: David V. Axene, FSA, CERA, FCA, MAAA

Vermont Health Care Cost and Utilization Report

Session 33 TS, Medicare Risk Scores for Beginners with Intermediate Topics. Moderator/Presenter: Joseph Saul Flaks, FSA, MAAA

Article from: Pension Section News. September 2013 Issue 81

Evidence-Based Program Reimbursement Strategies. Timothy P. McNeill, RN, MPH

Innovation in Health Care Delivery and Benefits

Clinic Comparison Reporting. June 30, 2016

Session 107 PD, Value of ACA Coding Improvement: Market Effects. Moderator: Douglas T. Norris, FSA, MAAA. Presenters: Ksenia Whittal, FSA, MAAA

Centers for Medicare & Medicaid Services: Innovation Center New Direction Request For Information: Medicare Advantage (MA) Innovation Models

Session 41PD, Is it Time to Review Your Trend Model? Moderator/Presenter: Joan C. Barrett, FSA, MAAA

Optum. Actuarial Toolbox Proven, sophisticated and market-leading actuarial models for health plans and benefits consultants

USES AND LIMITATIONS OF THE CLAIM AND CLAIM LINE FEED (CCLF)

Dual-eligible beneficiaries S E C T I O N

Understanding Your Medicare Options. Medicare Made Clear

Patient Protection and Affordable Care Act: HHS Notice of Benefit and Payment Parameters for 2014 Final Rule Summary.

In This Issue (click to jump):

UnitedHealthcare of California

Paper 8: Testing Actuarial Methods for Evaluating Disease Management Savings Outcomes

36 th Annual J.P. Morgan Healthcare Conference January 9, Bruce D. Broussard President & CEO

Transcription:

Rising risk: Maximizing the odds for care management Ksenia Whittal, FSA, MAAA Abigail Caldwell, FSA, MAAA Most healthcare organizations already know which members are currently costly, but what about one year from now? What if future high-risk and highcost members could be identified before they incur those costs? Healthcare organizations often seek to prevent high cost medical events while improving the quality of care. As a recent paper from Stanford University noted, proactively identifying and managing care for high-cost patients especially cost bloomers, who may disproportionately benefit from interventions to mitigate future high-cost years -- can be an effective way to simultaneously improve quality and reduce population health costs. 1 The MARA Rising Risk model arose from the need for a more precise method to proactively identify individuals for early intervention and care management that promotes appropriate and efficient use of limited resources. Rising Risk specifically focuses on predicting the individuals who are likely to have greater health care needs and higher expenditures near term, as compared to the current level of expenditures. In this analysis, we examine predictive models to determine if an enhanced model can better identify individuals with rising risk relative to traditional prospective risk adjustment models. We evaluate the ability of these models to select members whose costs increase in the future year. We found that a model that is specifically tuned to predict rising risk is an improvement for case selection and it outperforms traditional prospective risk adjustment models. If we consider the transition of members from a current year s risk level to the next year, there are three options the risk can increase, decrease, or remain largely unchanged (more precisely, here we mean very minor changes to an individual s health profile resulting in insignificant changes to the costs in either direction). The chart in Figure 1 illustrates the transition states from one year to the next. 1 PREDICTING PATIENT COST BLOOMS IN DENMARK: A LONGITUDINAL POPULATION-BASED STUDY. Available at: http://statweb.stanford.edu/~ljanson/papers/predicting_patient_cost_blooms_ In_Denmark-Tamang_ea-2016.pdf FIGURE 1: TRANSITION IN RISK FROM TO A common approach for identifying members for care management and interventions is to focus on the members who are currently high-cost, or expected to be high-cost next year (by using prospective risk adjustment scores). Both approaches cast a wide net that capture both quadrants on the right side of the chart high-risk members whose risks will be largely the same next year, and members who are currently high-cost but will revert to the mean by next year (decreasing risk cohort). A more refined approach would be to aim to maximize the proportion of members in the top two quadrants those whose risks will be increasing next year (top left) and high-risk members whose risks will be largely the same next year (top right). There are many existing tools to help care coordinators identify high-cost complex case members in order to reduce the persistent cost levels and prevent further deterioration, but the ultimate goal in care management has been finding the rising risk cohort of the population, implementing early interventions to focus on those members with increasing risk and addressing their additional healthcare needs before their costs escalate. In order to identify members whose risk levels will likely significantly change in the next year, we decided to develop a more precise method for member selection and stratification. Looking beyond diagnosis data, and even beyond prospective risk scores, we used predictive modeling techniques to identify more complex patterns and markers of the increasing costs with the goal of identifying members in that top left quadrant. The resulting model, Rising Risk model of the Milliman Advanced Risk Adjusters (MARA ), predicts the change in member risk (and therefore cost), in order to proactively identify members who Rising risk: Maximizing the odds for care management 1 March 2018

are more likely to experience a substantial change in cost, relative to their current cost levels. The next step was to test how different (and effective) these various methods of member selection and stratification are when you compare them side by side, using a single population. We considered the following three member selection methods that are commonly used: 1. Method 1: Select members with highest costs in a given year. This is the simplest method that does not require any advanced analytics and would be available to anyone with access to annual cost data for a population. Rank members from highest to lowest cost incurred in the most recent 12- month period, and select the top 15% for care management. 2 2. Method 2: Select members with highest prospective risk scores. This is a more sophisticated approach (and the most commonly used), where prospective risk adjustment is used to rank members from highest to lowest risk scores, and select the top 15% for care management.1 Prospective risk scores are predictions of resources used in the subsequent 12-month period, and rely on information on the diagnoses (and sometimes prescription medication claims) in a current 12-month period. 3. Method 3: Select members identified by the MARA Rising Risk model. The model outputs a binary flag (1 or 0), indicating which members are most likely to be in the rising risk category. Select these members for care management. The proportion of members flagged as rising risk can range anywhere from 10% to 20%, depending on the population. Analysis and results We used two consecutive years of claim experience for a commercially insured population, 3 and compared the cohorts identified by the three methods by asking the following questions: What proportion of each member cohort will actually experience a meaningful increase in cost, a meaningful decrease in cost, or no meaningful change in cost? What are the costs for these cohorts in each of the two years, in total and by major service category (inpatient hospital, outpatient setting, professional, and prescription drugs)? What is the utilization of services for these cohorts in each of the two years, in total and by major service category? The answer to the first question is presented in the charts in Figure 2. 2 15% was used in this analysis, and can certainly vary with the size of a population and the distribution of costs. 3 The case study analysis was run using Truven Marketscan data. Membership and claims were limited to members with 24 consecutive months of eligibility. FIGURE 2: DISTRIBUTION OF MEMBERS SELECTED FOR INTERVENTIONS UNDER EACH METHOD Method 1: Members with est Actual Cost 6% 10% 71% Method 2: Members with est Prospective Risk Score 25% Method 3: Members with Rising Risk Flag 49% 9% 53% 3% 35% Rising risk: Maximizing the odds for care management 2 March 2018

Targeting either the highest-cost (method 1) or the highest-risk (method 2) members identifies complex members with either many diagnoses or high-cost events observed during the most recent year. As a result, a large portion of these member cohorts (71% and 53%, respectively) are expected to experience a regression in cost over the next 12-month period, particularly after undergoing a one-time high-cost procedure or recovering from an acute condition. The MARA Rising Risk model (method 3), however, projected the highest proportion of members with increasing risk (49%) and the lowest proportion of members with decreasing risk (35%), both of which could enhance the efficiency of care management member selection. 4 To answer the last two questions about the magnitude of costs and utilization, we compared current and following year costs to evaluate how the costs changed between the two years. This information is presented in the tables in Figures 3 and 4 for each of these three cohorts during two consecutive years. FIGURE 3: AVERAGE ALLOWED COSTS FOR SELECTED COHORTS METHOD 1: MEMBERS WITH HIGHEST ACTUAL COST IP $6,380 $2,945 ($3,435) -54% $10,846 $8,080 ($2,767) -26% ER $589 $205 ($385) -65% RX $3,470 $3,525 $55 2% ALL SERVICES $21,286 $14,754 -$6,531-31% METHOD 2: MEMBERS WITH HIGHEST PROSPECTIVE RISK SCORE IP $4,864 $3,388 ($1,476) -30% $9,093 $8,563 ($530) -6% ER $458 $205 ($253) -55% RX $3,780 $3,890 $109 3% ALL SERVICES $18,195 $16,045 -$2,150-12% 4 Rising Risk members were identified as those with a ratio of Year 2 to Year 1 costs greater than 1.5. Falling Risk members had Year 2 to Year 1 cost ratios less than 0.90. members had Year 2 to Year 1 cost ratios between 0.90 and 1.5. FIGURE 3: AVERAGE ALLOWED COSTS FOR SELECTED COHORTS (CONTINUED) METHOD 3: MEMBERS WITH RISING RISK FLAG IP $167 $1,566 $1,399 838% $1,910 $3,897 $1,987 104% ER $106 $108 $2 2% RX $1,362 $1,551 $189 14% ALL SERVICES $3,544 $7,121 $3,577 101% The first striking difference in the Year 1 cost levels (column ) is rather obvious the rising risk cohort members are lower-cost members (~$3,500 per member per year [PMPY]), and the other two cohorts captured the most expensive members with the highest cost of over $18,000 and $21,000 PMPY. For a point of reference, the Year 1 cost in the entire population sample from which the three cohorts were selected was just over $4,600 PMPY. Total average cost PMPY doubled (increased by over 100%) for the rising risk cohort in Year 2 (~$7,100, see column ), while total average cost for the highest current cost and highest prospective risk score cohorts decreased. While emergency room (ER) costs stayed level for the rising risk cohort, these costs dropped significantly (more than 50%) for the other two cohorts. The costs for outpatient hospital and professional services increased by more than 100% for the rising risk cohort, which equated to the largest increase in average cost in absolute dollar amount across all service categories. However, it is the change in the inpatient hospital cost for the rising risk cohort that is most significant and noteworthy, with an 838% increase in average cost, particularly when contrasted with a large drop in inpatient costs in the other two cohorts (-54% and -30%, column ). We then broke down the overall cost per member per year into utilization (see columns ) and cost per patient (see columns ), in order to understand the driver behind the change in cost (see Figure 4 below). The notable changes in inpatient costs mentioned above can be attributed primarily to the change in utilization of these services in Year 2. While both the rising risk and current year high-cost cohorts showed an increase in inpatient costs per patient in Year 2 (column ), indicating hospital admissions of higher severity, the utilization of inpatient hospital by the rising risk cohort increased dramatically as well (columns and ). The utilization of inpatient hospital by the highest-cost and highest-risk cohorts decreased significantly, as one might have expected (columns and ). Rising risk: Maximizing the odds for care management 3 March 2018

FIGURE 4: COSTS AND UTILIZATION BY PATIENT FOR SELECTED COHORTS METHOD 1: MEMBERS WITH HIGHEST ACTUAL COST IP 35,751 11,700 (24,051) -67% $17,604 $24,831 $7,226 41% 98,430 95,829 (2,601) -3% $10,869 $8,317 ($2,553) -23% ER 37,284 18,336 (18,948) -51% $1,559 $1,101 ($458) -29% RX 90,193 86,559 (3,634) -4% $3,795 $4,017 $222 6% METHOD 2: MEMBERS WITH HIGHEST PROSPECTIVE RISK SCORE IP 21,123 14,878 (6,245) -30% $22,713 $22,461 ($253) -1% 98,331 97,317 (1,014) -1% $9,121 $8,679 ($442) -5% ER 30,785 18,706 (12,079) -39% $1,467 $1,081 ($386) -26% RX 89,906 88,609 (1,297) -1% $4,147 $4,330 $183 4% METHOD 3: MEMBERS WITH RISING RISK FLAG IP 2,437 7,079 4,642 190% $5,526 $17,838 $12,312 223% 68,968 69,104 136 0% $2,233 $4,548 $2,315 104% ER 9,344 10,276 932 10% $914 $847 ($67) -7% RX 57,875 54,141 (3,734) -6% $1,898 $2,311 $413 22% Next steps for care management Once a cohort of members has been identified for care management, there are additional steps that can be taken to further stratify and prioritize members within that cohort. Consider a case management application for stratifying a congestive heart failure (CHF) population to identify patients for management. When selecting members for a CHF disease management program, there is little specificity when simply identifying all members with CHF diagnosis as target participants. In our research data sample of approximately 650,000 individuals, 2,560 members have a diagnosis of CHF. This large number of patients can quickly overwhelm Disease Management (DM) staff with limited resources to assess and manage this population. To be more specific for both staff planning and addressing member needs, care managers could instead focus primarily on those CHF members who are more likely to experience a meaningful increase in cost by adding the Rising Risk flag, which yields a more manageable 924 members. Using the additional data and indicators provided by MARA, these 924 members can further be examined and prioritized by risk strata as shown in Figure 5, and first priority given to those members in the highest risk strata, for example. FIGURE 5: BREAKDOWN OF CHF RISING RISK MEMBERS CURRENT RELATIVE RISK CATEGORY VERY HIGH RISK 218 HIGH RISK 456 AVERAGE RISK 208 LOWER THAN AVERAGE RISK 40 VERY LOW RISK 2 NUMBER OF CHF RISING RISK MEMBERS Rising risk: Maximizing the odds for care management 4 March 2018

Conclusion There is certainly no single method when it comes to member stratification for care management. While it is only natural to focus attention on the highest cost members (the 20% in the 80/20 rule 5 ) in order to reduce those costs, focusing on members who will regress to the mean can be inefficient. Rising Risk prediction can prioritize the remaining 80% of the population more efficiently to identify the opportunity cases. An example of this can be seen in a recent study in Health Affairs, which found that the cost reductions among 2013 MSSP [Medicare Shared Savings Program] entrants were almost entirely concentrated among lower-risk patients. While this study highlights findings in a Medicare population specifically, the concept is worth exploring for other populations and is consistent with characteristics of cohort of members identified using Rising Risk model in this analysis. Using advanced analytics such as Rising Risk model offers a fresh perspective on the question of member prioritization and stratification. 50 http://www.commonwealthfund.org/~/media/files/publications/issue%20brief/ 2011/May/1501_Hall_risk_adjustment_ACA_guide_for_regulators_ib_v2.pdf Milliman is among the world s largest providers of actuarial and related products and services. The firm has consulting practices in life insurance and financial services, property & casualty insurance, healthcare, and employee benefits. Founded in 1947, Milliman is an independent firm with offices in major cities around the globe. milliman.com CONTACT Ksenia Whittal ksenia.whittal@milliman.com Abigail Caldwell abigail.caldwell@milliman.com 2018 Milliman, Inc. All Rights Reserved. The materials in this document represent the opinion of the authors and are not representative of the views of Milliman, Inc. Milliman does not certify the information, nor does it guarantee the accuracy and completeness of such information. Use of such information is voluntary and should not be relied upon unless an independent review of its accuracy and completeness has been performed. Materials may not be reproduced without the express consent of Milliman.